The FAVOUR study showed an ORR of 38.5% versus 46.2% for double/triple dose vomitinib (160 or 240 mg/day) in patients with EGFR ex20ins mutated NSCLC (49). This evidence concerns the gene EGFR and non-small cell lung carcinoma.